CD19 and non-Hodgkin lymphoma: Liu et al. [] also report preliminary data in a clinical trial of pediatric patients with B-cell lymphoid malignancies, including non-Hodgkin lymphoma, in regard to the use of anti-CD19, anti-CD20, or anti-CD22 CAR T-cell therapy in a sequential manner.